ColeHii
2021-11-11
👍🏻
Bristol-Myers Squibb completes $20M investment in Compugen
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":870584200,"tweetId":"870584200","gmtCreate":1636634647350,"gmtModify":1636634647665,"author":{"id":3569303342488537,"idStr":"3569303342488537","authorId":3569303342488537,"authorIdStr":"3569303342488537","name":"ColeHii","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":18,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍🏻</p></body></html>","htmlText":"<html><head></head><body><p>👍🏻</p></body></html>","text":"👍🏻","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/870584200","repostId":1171270648,"repostType":4,"repost":{"id":"1171270648","pubTimestamp":1636634175,"share":"https://www.laohu8.com/m/news/1171270648?lang=&edition=full","pubTime":"2021-11-11 20:36","market":"us","language":"en","title":"Bristol-Myers Squibb completes $20M investment in Compugen","url":"https://stock-news.laohu8.com/highlight/detail?id=1171270648","media":"seekingalpha","summary":"Compugen(NASDAQ:CGEN)shares are trading ~17.5% higher in the pre-market after announcing that Bristo","content":"<p>Compugen(NASDAQ:CGEN)shares are trading ~17.5% higher in the pre-market after announcing that Bristol-Myers Squibb(NYSE:BMY)has completed its $20M in the company.</p>\n<p>The investment follows the issuance of ~2.3M Compugen shares purchased by Bristol-Myers at ~$8.57 per share, indicating a 33% premium over the closing price on Nov. 09.</p>\n<p>In addition to the existing joint development committee at the operating level, a joint steering committee has been set up as part of the expansion of collaboration to oversee the programs that come under the partnership.</p>\n<p>\"Bristol Myers Squibb's strategic investment in Compugen strengthens our relationship and the goal of both companies to take forward our clinical studies conducted under our collaboration in bringing innovative therapies to cancer patients,” Compugen (CGEN) CEO Anat Cohen-Dayag said.</p>\n<li><p>In 2018, Bristol-Myers (BMY) teamed up with Compugen (CGEN) to evaluate anti-PVRIG antibody COM701 in combination with Opdivo (nivolumab) in patients with advanced solid tumors.</p></li>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol-Myers Squibb completes $20M investment in Compugen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol-Myers Squibb completes $20M investment in Compugen\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-11 20:36 GMT+8 <a href=https://seekingalpha.com/news/3769400-bristol-myers-squibb-completes-20m-investment-in-compugen><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Compugen(NASDAQ:CGEN)shares are trading ~17.5% higher in the pre-market after announcing that Bristol-Myers Squibb(NYSE:BMY)has completed its $20M in the company.\nThe investment follows the issuance ...</p>\n\n<a href=\"https://seekingalpha.com/news/3769400-bristol-myers-squibb-completes-20m-investment-in-compugen\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝","CGEN":"Compugen医疗"},"source_url":"https://seekingalpha.com/news/3769400-bristol-myers-squibb-completes-20m-investment-in-compugen","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1171270648","content_text":"Compugen(NASDAQ:CGEN)shares are trading ~17.5% higher in the pre-market after announcing that Bristol-Myers Squibb(NYSE:BMY)has completed its $20M in the company.\nThe investment follows the issuance of ~2.3M Compugen shares purchased by Bristol-Myers at ~$8.57 per share, indicating a 33% premium over the closing price on Nov. 09.\nIn addition to the existing joint development committee at the operating level, a joint steering committee has been set up as part of the expansion of collaboration to oversee the programs that come under the partnership.\n\"Bristol Myers Squibb's strategic investment in Compugen strengthens our relationship and the goal of both companies to take forward our clinical studies conducted under our collaboration in bringing innovative therapies to cancer patients,” Compugen (CGEN) CEO Anat Cohen-Dayag said.\nIn 2018, Bristol-Myers (BMY) teamed up with Compugen (CGEN) to evaluate anti-PVRIG antibody COM701 in combination with Opdivo (nivolumab) in patients with advanced solid tumors.","news_type":1},"isVote":1,"tweetType":1,"viewCount":795,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/870584200"}
精彩评论